Tenax Therapeutics TENX 深 滬
等待開盤 11-04 09:30:00 美东时间
1.84
+0.040
+2.22%
華盛通- 最 高1.92
- 今 開1.81
- 成交量 249.34万股
- 最 低 1.79
- 昨 收 1.80
- 總市值 6886.00万
- 52周最高 19.40
- 市盈率 靜 --
- 換手率 6.66%
- 52周最低 1.31
- 委 比 -90.08%
- 總股本 3742.39万
- 歷史最高 364800.00
- 量 比 1.59
- 振 幅 7.22%
- 歷史最低 1.31
- 每 手 1
- 風險率 5.08%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Tenax Therapeutics Inc.收跌1.06%，成交额469.25万美元
10月30日，Tenax Therapeutics Inc.（TENX）收跌1.06%，报1.86美元，成交额469.25万美元，市值6960.85万美元。 行...
10-30 07:14
Tenax Therapeutics Inc.收跌4.65%，成交额209.1万美元
10月27日，Tenax Therapeutics Inc.（TENX）收跌4.65%，报1.64美元，成交额209.1万美元，市值6137.52万美元。 行情...
10-27 07:18
Tenax Therapeutics Inc.收跌9.93%，成交额262.36万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 07:28
Guggenheim Downgrades Tenax Therapeutics to Neutral
Guggenheim analyst Seamus Fernandez downgrades Tenax Therapeutics (NASDAQ:TENX) from Buy to Neutral.
08-31 20:55
Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026
<p>Tenax Therapeutics announced positive results from the Phase 3 LEVEL trial of TNX-103 for pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). In patients with baseline 6MWD below 333 meters, TNX-103 showed a 26.3-meter improvement in 6MWD, a 47% reduction in NT-proBNP, and a 4.9 mmHg reduction in RVSP compared to placebo. These findings suggest TNX-103 may provide clinical benefits for PH-HFpEF patients, pa...
08-29 12:21
Tenax rises on over $1.8M insider buying
Cardiopulmonary drug developer Tenax Therapeutics (TENX) added nearly 13% in the premarket trading on Tuesday after Adar1 Capital Management, one of its key shareholders, bought more than $1.8M worth ...
08-25 19:36
美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
Chardan Capital Downgrades Tenax Therapeutics to Neutral, Lowers Price Target to $5
Chardan Capital analyst Gautam Chukka downgrades Tenax Therapeutics (NASDAQ:TENX) from Buy to Neutral and lowers the price target from $27 to $5.
08-12 00:02
Tenax Therapeutics Reports Phase 3 LEVEL Trial Of TNX‑103 In PH‑HFpEF; Study Did Not Meet Primary Or Key Secondary Endpoints
TNX-103 did not meet statistical significance on the primary endpoint of improvement in 6-minute walk distance versus placebo In prespecified exploratory analyses in the overall trial population, treatment with TNX-103 resulted in a 49% greater reduction in NT-proBNP compared to placebo (nominal p<0...
08-10 19:07
Tenax Therapeutics Q2 EPS $(0.35) Beats $(0.37) Estimate
Tenax Therapeutics (NASDAQ:TENX) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.37) by 5.41 percent. This is a 29.63 percent decrease over losses of $(0.27) per share from the same period last year.
07-31 19:30
